Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXCELIS TECHNOLOGIES INCACLS · Entity 4152 | Director | February 17, 2021 | February 17, 2021 |
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director | October 01, 2026 | October 03, 2026 |
| KORU Medical Systems, Inc.KRMD · Entity 6517 | Director · Chairman of the Board | October 01, 2026 | October 01, 2026 |
| Vyant Bio, Inc.VYNT · Entity 116415 | Director | January 17, 2023 | January 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXCELIS TECHNOLOGIES INC
Report date February 17, 2021 · Filed February 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,354 |
Reported balance
After 2021-02-17 transaction · row 1
1 source rowRow 1 · 2021-02-17 · Sale · Disposed 6,881 · Balance 1,354 |
ClearPoint Neuro, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,004 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 993 · Balance 132,004 F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026.
KORU Medical Systems, Inc.
Report date October 01, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 239,836 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 7,679 · Balance 239,836 |
Vyant Bio, Inc.
Report date January 17, 2023 · Filed January 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 23,895 |
Reported balance
After 2023-01-17 transaction · row 1
1 source rowRow 1 · 2023-01-17 · Grant · Acquired 4,368 · Balance 23,895 F1: On January 17, 2023, the Reporting Person was granted 4,368 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2024, so long as Reporting Person remains a director through that date. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectBy R. John Fletcher 2015 Revocable Trust | 6,060 |
Reported balance
Holding disclosure · report date 2023-01-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,060 |
Filing footnotes · ownership attribution and instrument terms
F1: On January 17, 2023, the Reporting Person was granted 4,368 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2024, so long as Reporting Person remains a director through that date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 5,666 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 3,566 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.75 · Expires 2032-04-26 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 4,266 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
SPECTRANETICS CORP
Report date August 09, 2017 · Filed August 11, 2017
Section 16 reporting ended · disclosed 2017-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SPNC Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-09 transaction · row 1
1 source rowRow 1 · 2017-08-09 · Disposition to issuer · Disposed 141,697 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes. F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes.
F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2019 Filed Dec 12, 2019 21:11 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | SaleCommon Stock | 20,000 | $23.52 | $470,400.00 |
DisclosureSEC source: 0001209191-19-060205 · doc4.xml · nonDerivative · entry 3 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,104 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.50 to $23.61, inclusive. The reporting person undertakes to provide to Axcelis Technologies, Inc., any security holder of Axcelis Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 21:11 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionCommon Stock | 10,000 | $7.20 | $72,000.00 |
DisclosureSEC source: 0001209191-19-060205 · doc4.xml · nonDerivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 21:11 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionCommon Stock | 10,000 | $6.40 | $64,000.00 |
DisclosureSEC source: 0001209191-19-060205 · doc4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:37 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001209191-19-060082 · doc4.xml · derivative · entry 5 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:37 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-19-060082 · doc4.xml · derivative · entry 4 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2020-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:37 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | SaleCommon Stock | 22,500 | $22.96 | $516,600.00 |
DisclosureSEC source: 0001209191-19-060082 · doc4.xml · nonDerivative · entry 3 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,104 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.88 to $23.06, inclusive. The reporting person undertakes to provide to Axcelis Technologies, Inc., any security holder of Axcelis Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:37 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionCommon Stock | 10,000 | $7.96 | $79,600.00 |
DisclosureSEC source: 0001209191-19-060082 · doc4.xml · nonDerivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:37 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionCommon Stock | 12,500 | $6.40 | $80,000.00 |
DisclosureSEC source: 0001209191-19-060082 · doc4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,355 | $5.15 | $12,128.25 |
DisclosureSEC source: 0001534424-19-000269 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,212 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2019. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:40 UTC | KORU Medical Systems, Inc. REPR · Entity 6517 | GrantCommon Stock | 1,582 | $3.95 | $6,248.90 |
DisclosureSEC source: 0001161697-19-000414 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,942 Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 3,829 | $3.17 | $12,137.93 |
DisclosureSEC source: 0001534424-19-000196 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,857 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.17 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 28, 2019. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:57 UTC | KORU Medical Systems, Inc. REPR · Entity 6517 | GrantCommon Stock | 1,312 | $2.88 | $3,778.56 |
DisclosureSEC source: 0001161697-19-000283 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,360 Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 20:24 UTC | KORU Medical Systems, Inc. REPR · Entity 6517 | GrantCommon Stock | 16,048 | $2.18 | $34,984.64 |
DisclosureSEC source: 0001161697-19-000246 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,048 Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 20:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001534424-19-000173 · ownership.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2020 annual meeting of stockholders. Read SEC document |
| May 15, 2019 Filed May 15, 2019 21:15 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | GrantCommon Stock | 6,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030089 · doc4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,104 F1 · price: These shares are issuable on vesting of restricted stock units granted under the Company's 2012 Equity Incentive Plan. Assuming continuation of service on the Board of Directors, these restricted stock units will vest on November 15, 2019. F2 · balance_after: Of the shares held as of May 15, 2019, 6,232 were issuable on vesting of restricted stock units granted to the director under the 2012 Equity Incentive Plan and are subject to forfeiture. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:11 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 3,854 | $3.15 | $12,140.10 |
DisclosureSEC source: 0001534424-19-000101 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,028 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2019. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 20:45 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001209191-19-019182 · doc4.xml · derivative · entry 6 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 20:45 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-19-019182 · doc4.xml · derivative · entry 5 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2019-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 20:45 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | SaleCommon Stock | 10,000 | $20.27 | $202,700.00 |
DisclosureSEC source: 0001209191-19-019182 · doc4.xml · nonDerivative · entry 4 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,872 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.34, inclusive. The reporting person undertakes to provide to Axcelis Technologies, Inc., any security holder of Axcelis Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 20:45 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionCommon Stock | 10,000 | $3.72 | $37,200.00 |
DisclosureSEC source: 0001209191-19-019182 · doc4.xml · nonDerivative · entry 3 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 20:45 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | SaleCommon Stock | 12,500 | $20.26 | $253,250.00 |
DisclosureSEC source: 0001209191-19-019182 · doc4.xml · nonDerivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,872 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.36, inclusive. The reporting person undertakes to provide to Axcelis Technologies, Inc., any security holder of Axcelis Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 20:45 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionCommon Stock | 12,500 | $1.76 | $22,000.00 |
DisclosureSEC source: 0001209191-19-019182 · doc4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 22:15 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 8,248 | $1.47 | $12,124.56 |
DisclosureSEC source: 0001534424-19-000013 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,174 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2018. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:37 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 6,900 | $1.76 | $12,144.00 |
DisclosureSEC source: 0001534424-18-000335 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,926 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.76 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 28, 2018. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 5,394 | $2.18 | $11,758.92 |
DisclosureSEC source: 0001534424-18-000238 · fletcher.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,026 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.18 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 29, 2018. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 12:46 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001534424-18-000206 · fletcher.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2019 annual meeting of stockholders. Read SEC document |
| May 16, 2018 Filed May 17, 2018 12:11 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | GrantCommon Stock | 5,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030758 · doc4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,872 F1 · price: These shares are issuable on vesting of restricted stock units granted under the Company's 2012 Equity Incentive Plan. Assuming continuation of service on the Board of Directors, these restricted stock units will vest on November 16, 2018. F2 · balance_after: Of the shares held as of May 16, 2018, 5,637 were issuable on vesting of restricted stock units granted to the director under the 2012 Equity Incentive Plan and are subject to forfeiture. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 20:51 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 3,632 | $3.13 | $11,368.16 |
DisclosureSEC source: 0001534424-18-000110 · fletcher.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,632 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.13 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2018. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:17 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 13,875 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001534424-17-000498 · fletcher.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,875 Underlying: Common Stock · 13,875 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2018 annual meeting of stockholders. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 14:35 UTC | SPECTRANETICS CORP SPNC · Entity 173862 | Disposition to issuerSPNC Common Stock | 141,697 | $38.50 | $5,455,334.50 |
DisclosureSEC source: 0001179110-17-011362 · edgar.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes. F2 · shares: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 17:22 UTC | SPECTRANETICS CORP SPNC · Entity 173862 | GrantSPNC Common Stock | 4,780 | $0.00 | $0.00 |
DisclosureSEC source: 0000789132-17-000093 · wf-form4_149730254393414.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,697 F1 · shares: Director compensation grant of SPNC restricted stock, vesting over 1 year, 100% vested on 6/8/2018. Read SEC document |
| May 17, 2017 Filed May 17, 2017 20:43 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | GrantCommon Stock | 3,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033137 · doc4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,235 F1 · price: These shares are issuable on vesting of restricted stock units granted under the Company's 2012 Equity Incentive Plan. Assuming continuation of service as a director, 100% of these restricted stock units will vest on November 17, 2017. F2 · balance_after: Of the shares held on May 17, 2017, 3,802 were issuable on vesting of restricted stock units granted to the executive under the 2012 Equity Incentive Plan and are subject to forfeiture. Read SEC document |
| May 09, 2017 Filed May 11, 2017 12:33 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001534424-17-000184 · fletcher1.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125 Underlying: Common Stock · 1,125 shares Expires 2027-05-09 F1 · derivative.exercise_date: The shares subject to this option vest ratably on the first, second and third anniversaries of the grant date, May 9, 2018, May 9, 2019 and May 9, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.